Status
Conditions
Treatments
About
The goal of this clinical trial is to examine the effect of vagus nerve stimulation (VNS) on chronic, widespread pain in adults. The study will also evaluate which method of VNS-electrical ear stimulation or deep exhalation breathing-has a more significant impact on pain intensity, quality of life, and emotional well-being.
The main questions it aims to answer are:
Does vagus nerve stimulation reduce pain intensity in individuals with chronic, widespread pain?
Which intervention-electrical ear stimulation or deep exhalation breathing-provides a greater improvement in autonomic function, emotional status, and quality of life?
Researchers will compare two active interventions-electrical ear stimulation and deep exhalation breathing-to a no-treatment control group to determine relative effectiveness on pain and related outcomes.
Participants will:
Be randomly assigned to one of three groups:
Complete four questionnaires to assess pain, emotional state, and quality of life.
Undergo physiological assessments including heart rate variability, neck muscle tissue flexibility (via MyotonPro), and pressure pain sensitivity (via pressure algometer), both before and after the 2-week period.
Participation includes two in-person sessions (approximately 1 hour each) and daily home practice (for intervention groups) lasting 40-60 minutes per day for two weeks. The study involves minimal risk, and no compensation is provided. Participation is voluntary, and confidentiality will be strictly maintained.
Full description
Detailed Description:
Study Overview:
This randomized controlled clinical trial investigates the effects of two forms of non-invasive vagus nerve stimulation (VNS) on chronic widespread pain (CWP). The study is designed to explore whether stimulating the vagus nerve through auricular electrical stimulation (AES) or deep forced exhalation (DFE) improves pain, muscle stiffness, and functional status in individuals with CWP.
Vagal nerve stimulation (VNS) has been associated with modulation of the autonomic nervous system, leading to downstream effects on inflammation, pain perception, and emotional regulation. This study compares the effectiveness of these two intervention methods with a control group that receives no treatment during the study period.
Research Questions:
Hypotheses:
Study Procedures and Assessments:
Participants will be randomly assigned to one of three groups:
Heart Rate Variability (HRV):
Assessed using the Polar H10 chest strap sensor.
Muscle Stiffness and Tissue Compliance:
Measured using the MyotonPRO device on the upper trapezius. • Equipment preparation: The MyotonPRO is calibrated before each session.
• Participant setup: The participant wears clothing that allows shoulder access and avoids caffeine, alcohol, or vigorous activity for at least 2 hours prior. The participant lies supine for at least 5 minutes before testing.
• Measurement: The skin is cleaned and the midpoint of the trapezius marked. The probe is placed perpendicular to the skin, and 3-5 consecutive measurements are taken on each side. The device records stiffness (N/m), elasticity, relaxation time, frequency, and compliance. Data is stored under a participant ID for analysis.
Pain Pressure Threshold (PPT):
Assessed with a handheld analog pressure algometer at three locations: mid trapezius, L5 lumbar paraspinal, and gastrocnemius-soleus junction.
Pain Level:
Measured using the Visual Analog Scale (VAS), a 10 cm line from "no pain" to "worst pain imaginable."
Quality of Life:
Measured with the Quality of Life Scale (QOLS), covering physical, emotional, and social domains.
Emotional State:
Assessed using the Positive and Negative Affect Schedule (PANAS), which rates 10 positive and 10 negative emotions.
Depression Severity:
Evaluated using the Patient Health Questionnaire-9 (PHQ-9), a 9-item tool commonly used in research and clinical practice.
Intervention Protocols:
Auricular Electrical Stimulation (AES):
• Objective: Stimulate the auricular branch of the vagus nerve (ABVN) using taVNS.
• Site: Cymba conchae of the left ear.
• Equipment: Standard taVNS device, clip electrodes with conductive gel, timer, and alcohol swabs.
• Stimulation Parameters:
o Waveform: Biphasic rectangular
o Pulse width: 200-300 µs
o Frequency: 20 Hz
o Intensity: Starting at 0.1 mA, increased until tingling is comfortable but not painful
o Duration: 20 minutes per session, twice daily for 2 weeks
• Contraindications: Cardiac arrhythmia, implanted pacemakers, pregnancy, epilepsy, skin infection at site, metal implants near ear.
Deep Forced Exhalation (DFE):
• Objective: Stimulate vagal tone through autonomic regulation via breathwork.
Control Group:
Participants undergo all pre- and post-study assessments but receive no intervention during the two-week period. They are debriefed afterward and may opt to receive either treatment following data collection.
Safety Considerations:
Potential AES risks include local irritation, tingling, warmth, lightheadedness, or bradycardia. All participants are screened and monitored during the first session. Instructions emphasize safe positioning, hydration, and gradual adjustment of intensity. Participants are advised to stop the session and contact the research team if they feel unwell.
DFE carries low risk, with occasional lightheadedness or fatigue reported. This is minimized by recommending seated practice and gradual breath intensity. Participants are asked to rest after each session.
Expected Benefits:
Participants may experience decreased pain sensitivity, improved autonomic regulation, better emotional well-being, and improved quality of life. These outcomes are not guaranteed, and no monetary compensation is offered for participation.
Contact Information:
Dr. Reza Nourbakhsh Email: Reza.nourbakhsh@ung.edu Phone: 706-864-1766
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Adults 18 years of age or older
Diagnosed by a healthcare provider with chronic widespread pain or fibromyalgia
Exclusion criteria
Cardiovascular disorders: Such as arrhythmia (irregular heartbeat), heart failure, coronary artery disease, or history of heart surgery
Neurological disorders: Including epilepsy, Parkinson's disease, multiple sclerosis, neuropathy, or seizures
Endocrine disorders: Such as uncontrolled diabetes, thyroid disease (hypothyroidism or hyperthyroidism), or adrenal disorders
Gastrointestinal disorders: Including inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel syndrome, or chronic acid reflux (GERD)
Respiratory disorders: Such as asthma, chronic bronchitis, emphysema, or sleep apnea
Vestibular disorders: Including Meniere's disease, benign paroxysmal positional vertigo (BPPV), or any condition causing balance problems
History of concussion or traumatic brain injury
Frequent dizziness or vertigo: History of unexplained or recurring episodes
Chronic or recurrent headaches: Including migraines, tension-type headaches, or cluster headaches
Ear problems: History of ear infections, hearing loss, tinnitus (ringing in the ears), or ear surgeries
Throat problems: History of chronic sore throat, difficulty swallowing (dysphagia), or throat surgery
Herniation: History of any type of herniation such as spinal disc herniation, inguinal (groin) hernia, or abdominal hernia
Skin sensitivity to electrical stimulation: Known allergic reaction, rash, or irritation from electrode pads or electrical devices applied to the skin
Primary purpose
Allocation
Interventional model
Masking
100 participants in 3 patient groups
Loading...
Central trial contact
Mohammad Reza Nourbakhsh, PT, Ph.D.; Rachael Wlton-Mouw, PT, DPT
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal